DL-homotyrosine | 96576-07-7

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: DL-homotyrosine
• 英文别名: LD-homotyrosine；2-amino-4-(4-hydroxy-phenyl)-butyric acid；2-Amino-4-(4-hydroxy-phenyl)-buttersaeure；Homotyrosin；2-azaniumyl-4-(4-hydroxyphenyl)butanoate
• CAS: 96576-07-7
• 化学式: C₁₀H₁₃NO₃
• mdl: MFCD03425896
• 分子量: 195.218
• InChiKey: LOOZZTFGSTZNRX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.6
• 重原子数：
  14
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  83.6
• 氢给体数：
  3
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  DL-homotyrosine 、 乙酸酐 以 溶剂黄146 为溶剂， 以95%的产率得到N-acetyl-homotyrosine
  参考文献：
  名称：

  Homotyrosine-Containing Cyanopeptolins 880 and 960 and Anabaenopeptins 908 and 915 from Planktothrix agardhii CYA 126/8

  摘要：

  Two homotyrosine-bearing cyanopeptolins are described from Planktothrix agardhii CYA 126/8. The compounds feature a common homotyrosine-containing cyclohexadepsipeptide and differ by sulfation of an exocyclically located 2-O-methyl-D-glyceric acid residue. In addition we describe two anabaenopeptins, which contain two homotyrosine residues, one of which is N-methylated. The anabaenopeptins have a common cyclopentapeptide portion and differ in the amino acid linked to it via an ureido bond, arginine and tyrosine, respectively.

  DOI：

  10.1021/np800557m
• 作为产物：
  描述：

  4-(2-溴乙基)苯胺盐酸盐(1:1) 在 乙醇 、 硫酸 、 sodium nitrite 作用下， 生成 DL-homotyrosine
  参考文献：
  名称：

  309.酪氨酸的同系物α-氨基-γ-（对羟基苯基）丁酸的合成

  摘要：

  DOI：

  10.1039/jr9470001571

文献信息

• [EN] BACKBONE-CYCLIZED PEPTIDOMIMETICS<br/>[FR] PEPTIDOMIMÉTIQUES À SQUELETTE CYCLISÉ
  申请人：POLYPHOR AG

  公开号：WO2016162127A1

  公开（公告）日：2016-10-13

  Novel backbone-cyclized peptidomimetics of the general formula cyclo[-P1-P2-P3-P4-P5-P6-P7-P8-T1-T2-] (I) wherein the single elements T or P are α-amino acid residues connected in either direction which, depending on their positions in the chain, are as defined in the description and the claims, and salts thereof, have the property to modulate the GLP-1 receptor. They can be used as medicaments to treat, prevent, or delay the onset of diseases, disorders or conditions in which modulation of the human GLP-1 receptor is beneficial, such as type 2 diabetes. These backbone-cyclized peptidomimetics can be manufactured by a process which is based on a mixed solid- and solution phase synthetic strategy.

  新型的骨架环化肽类似物的一般公式为cyclo[-P1-P2-P3-P4-P5-P6-P7-P8-T1-T2-]（I），其中单个元素T或P是α-氨基酸残基，以任一方向连接，根据它们在链中的位置，在描述和权利要求中定义，以及其盐，具有调节GLP-1受体的特性。它们可用作药物治疗、预防或延缓调节人类GLP-1受体有益的疾病、紊乱或病况，如2型糖尿病。这些骨架环化肽类似物可通过基于混合固相和溶液相合成策略的过程制造。
• [EN] INHIBITORS OF GROWTH FACTOR ACTIVATION ENZYMES<br/>[FR] INHIBITEURS D'ENZYMES D'ACTIVATION DE FACTEUR DE CROISSANCE
  申请人：UNIV WASHINGTON

  公开号：WO2016144654A1

  公开（公告）日：2016-09-15

  The present invention generally relates to compounds that are useful for inhibiting one or more of hepatocyte growth factor activator, matriptase, hepsin, Factor Xa, or thrombin. The present invention also relates to various methods of using the inhibitor compounds including treating a malignancy, a pre-malignant condition, or cancer by administering an effective amount of the inhibitor to a subject in need thereof.

  本发明通常涉及对抑制肝细胞生长因子激活剂、麦曲丝蛋白、赫普星、Xa因子或凝血酶等的化合物有用的化合物。本发明还涉及使用抑制剂化合物的各种方法，包括通过向需要的受试者施用有效量的抑制剂来治疗恶性肿瘤、癌前病变或癌症。
• [EN] BETA-HAIRPIN PEPTIDOMIMETICS<br/>[FR] PEPTIDOMIMÉTIQUES EN ÉPINGLE À CHEVEUX BÊTA
  申请人：POLYPHOR AG

  公开号：WO2016150576A1

  公开（公告）日：2016-09-29

  Beta-hairpin peptidomimetics of the general formula (I), and pharmaceutically acceptable salts thereof, with P, T, Q., and optionally L being elements as defined in the description and the claims, have Gram-negative antimicrobial activity to e.g. inhibit the growth or to kill microorganisms such as Klebsiellapneumoniae and/or Acinetobacter baumannii and/or Escherichia coli and/or Pseudomonas aeruginosa. They ca n be used as medicaments to treat or prevent infections or as disinfectants for foodstuffs, cosmetics, medicaments or other nutrient-containing materials. These peptidomimetics can be manufactured by a process which is based on a mixed solid- and solution phase synthetic strategy.

  Beta-发夹仿生肽的一般公式（I），及其药学上可接受的盐，其中P、T、Q.，以及可选的L作为描述和权利要求中定义的元素，具有抗革兰氏阴性微生物活性，例如抑制生长或杀灭肺炎克雷伯菌、包括鲍曼不动杆菌、大肠杆菌和铜绿假单胞菌等微生物。它们可用作药物治疗或预防感染，或用作食品、化妆品、药物或其他含营养物质的材料的消毒剂。这些仿生肽可以通过基于混合固相和溶液相合成策略的过程制造。
• Lyngbyaureidamides A and B, two anabaenopeptins from the cultured freshwater cyanobacterium Lyngbya sp. (SAG 36.91)
  作者：Jiachen Zi、Daniel D. Lantvit、Steven M. Swanson、Jimmy Orjala

  DOI：10.1016/j.phytochem.2011.09.017

  日期：2012.2

  Two anabaenopeptin-type peptides, lyngbyaureidamides A and B, together with two previously reported peptides lyngbyazothrins C and D, were isolated from the cultured freshwater cyanobacterium Lyngbya sp. (SAG 36.91). Their structures were determined by spectroscopic and chemical methods. Lyngbyazothrins C and D were also able to inhibit the 20S proteasome with IC(50) values of 7.1 μM and 19.2 μM, respectively

  从培养的淡水蓝藻 Lyngbya sp. 中分离出两种鱼腥藻肽类肽，lyngbyaureidamides A 和 B，以及两个先前报道的肽 lyngbyazothrins C 和 D。(SAG 36.91)。它们的结构是通过光谱和化学方法确定的。Lyngbyazothrins C 和 D 也能够抑制 20S 蛋白酶体，IC(50) 值分别为 7.1 μM 和 19.2 μM，而 lyngbyaureidamides A 和 B 在 50 μM 时没有活性。
• Diagnostic and therapeutic agents
  申请人：Taube Seija

  公开号：US20070258899A1

  公开（公告）日：2007-11-08

  Tumor targeting units are disclosed which have a peptide sequence C y —Y—G-F—X—W-G-Z-C yy (SEQ ID NO: 25), or a pharmaceutically or physiologically acceptable salt thereof. Tumor targeting agents are also disclosed having at least one targeting unit, directly or indirectly coupled to at least one effector unit. Diagnostic or pharmaceutical compositions having at least one targeting unit or at least one targeting agent, and targeting units or targeting agents for the preparation of a medicament for the treatment of cancer related diseases (including cancer), especially for the treatment of colon/colorectal cancer or its metastases are also disclosed.

  揭示了具有肽序列Cy—Y—G-F—X—W-G-Z-Cyy（序列ID编号：25）或其药学或生理上可接受的盐的肿瘤靶向单元。还披露了具有至少一个靶向单元的肿瘤靶向剂，直接或间接地偶联至至少一个效应单元。还披露了具有至少一个靶向单元或至少一个靶向剂的诊断或药物组合物，以及用于制备治疗癌症相关疾病（包括癌症）的药物的靶向单元或靶向剂，特别是用于治疗结肠/结直肠癌或其转移的靶向单元或靶向剂。